Related Experiment Video

Updated: Feb 23, 2026

Author Spotlight: THP-1 Macrophage Response to LPS/ATP — Unveiling the Pyroptosis, Apoptosis, and Necroptosis Spectrum
06:12

Author Spotlight: THP-1 Macrophage Response to LPS/ATP — Unveiling the Pyroptosis, Apoptosis, and Necroptosis Spectrum

Published on: May 3, 2024

3.5K

Global patent landscape of programmed cell death 1: implications of the rapid expansion

Xiangjun Kong1, Qianru Zhang1,2, Yunfeng Lai1

  • 1a Institute of Chinese Medical Sciences, State Key Laboratory of Quality Research in Chinese Medicine , University of Macau , Macao , China.

Expert Opinion on Therapeutic Patents
|September 12, 2017
PubMed
Abstract

Insights

The global patent landscape for programmed cell death 1 (PD-1) inhibitors is complex and rapidly evolving. Understanding this patent thicket is crucial for navigating intellectual property rights in cancer treatment development.

Area of Science:

  • Oncology
  • Immunology
  • Intellectual Property Law

Background:

  • Programmed cell death 1 (PD-1) inhibitors represent a significant advancement in cancer therapy.
  • The multi-billion dollar market and clinical success drive intense research and patent protection.

Purpose of the Study:

  • To clarify the global patent landscape for PD-1 inhibitors.
  • To identify trends and potential challenges in patenting related to PD-1 therapies.

Main Methods:

  • Analysis of 1287 patent families.
  • Examination of global patenting activities and trends.
  • Assessment of patent filing countries, ownership, co-patents, technical areas, and citation relationships.

Main Results:

  • Rapid expansion of patenting activities in recent years.
  • Fragmented ownership and dense technological interconnections observed.
  • Complex citation relationships indicate potential for patent conflicts.

Conclusions:

  • The PD-1 inhibitor field presents a potential patent thicket due to fragmented ownership and complex interdependencies.
  • Patent applicants must be aware of legal uncertainties and potential disputes.
  • Strategic patent development is essential for navigating this evolving landscape.
Keywords:
Programmed cell death 1 (PD-1)co-patentimmunotherapypatent citation networkpatent landscapetechnology flow

More Related Videos

Evaluation of Caspase Activation to Assess Innate Immune Cell Death10:23

Evaluation of Caspase Activation to Assess Innate Immune Cell Death

Published on: January 20, 2023

3.9K
Use of LysoTracker to Detect Programmed Cell Death in Embryos and Differentiating Embryonic Stem Cells12:44

Use of LysoTracker to Detect Programmed Cell Death in Embryos and Differentiating Embryonic Stem Cells

Published on: October 11, 2012

24.0K

Related Concept Videos

Overview of Cell Death01:30

Overview of Cell Death

Cell death is an essential process where the body gets rid of old or damaged cells. Cell proliferation and death need to be balanced, as an imbalance between the two may lead to cancer or autoimmune diseases.
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the...
10.4K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
8.9K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
8.8K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.4K
Autophagic Cell Death01:18

Autophagic Cell Death

Christian de Duve discovered “autophagy,” a process in which cellular components are engulfed by membrane-bound organelles called autophagosomes. The autophagosomes then fuse with lysosomes to digest the enclosed contents. Autophagy is generally activated in cells to prevent cell death. However, cell death is triggered when the damage is beyond repair.
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...
4.7K